Literature DB >> 23384962

Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect.

Gillian E Hanley1, Ursula Brain, Tim F Oberlander.   

Abstract

BACKGROUND: Prenatal exposure to serotonin reuptake inhibitor (SRI) antidepressants has been associated with delays in early developmental milestones, but there remains uncertainty. Even among a subset of studies examining the Bayley Scales of Infant Development (BSID), some have reported normal mental and psychomotor development while others have suggested a delay in motor development. Given an increasing number of infants exposed to SRIs, furthering our understanding of the possible developmental implications of SRI exposure in utero is critical. AIMS: To examine the effects of prenatal serotonin reuptake inhibitor exposure and maternal mood on infant developmental outcomes at 10months of age. STUDY
DESIGN: Prospective study of mothers and their 10-month-old infants.
SUBJECTS: We examined 31 mother-child pairs exposed prenatally to SRIs and 52 mother-child pairs who were nonexposed. OUTCOME MEASURE: The Bayley Scales of Infant Development (third edition) scores.
RESULTS: Infants exposed prenatally to SRIs scored significantly lower than nonexposed infants on gross motor (P=0.03), social-emotional (P=0.04) and adaptive behavior (P=0.05) subscales of the BSID-III, controlling for pre- and postnatal maternal depressed mood, smoking and alcohol use during pregnancy. No significant differences in any of the BSID-III subscales were observed between infants exposed and infants nonexposed to pre and postnatal maternal depressed mood (P>0.05). Increased levels of maternal positive affect at 10 months predicted increased social-emotional scores (P=0.03).
CONCLUSIONS: Infants prenatally exposed to SRIs score significantly lower on the gross motor, social-emotional and adaptive behavior subscales of the BSID-III, and this was not explained by underlying maternal depression.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23384962     DOI: 10.1016/j.earlhumdev.2012.12.012

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  34 in total

1.  Behavioural effects of fetal antidepressant exposure in a Norwegian cohort of discordant siblings.

Authors:  Ragnhild Eek Brandlistuen; Eivind Ystrom; Malin Eberhard-Gran; Irena Nulman; Gideon Koren; Hedvig Nordeng
Journal:  Int J Epidemiol       Date:  2015-04-14       Impact factor: 7.196

Review 2.  A role for the serotonin reuptake transporter in the brain and intestinal features of autism spectrum disorders and developmental antidepressant exposure.

Authors:  Kara Gross Margolis
Journal:  J Chem Neuroanat       Date:  2017-02-14       Impact factor: 3.052

3.  Transgenerational hypocortisolism and behavioral disruption are induced by the antidepressant fluoxetine in male zebrafish Danio rerio.

Authors:  Marilyn N Vera-Chang; Antony D St-Jacques; Rémi Gagné; Chris J Martyniuk; Carole L Yauk; Thomas W Moon; Vance L Trudeau
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-10       Impact factor: 11.205

Review 4.  Developmental changes in serotonin signaling: Implications for early brain function, behavior and adaptation.

Authors:  S Brummelte; E Mc Glanaghy; A Bonnin; T F Oberlander
Journal:  Neuroscience       Date:  2016-02-22       Impact factor: 3.590

5.  Neonatal adaptation following intrauterine antidepressant exposure: assessment, drug assay levels, and infant development outcomes.

Authors:  Megan Galbally; Olav Spigset; Andrew R Johnson; Rolland Kohan; Martha Lappas; Andrew J Lewis
Journal:  Pediatr Res       Date:  2017-08-16       Impact factor: 3.756

6.  Behavior and inhibitory control in children with prenatal exposure to antidepressants and medically untreated depression.

Authors:  Tone Kristine Hermansen; Espen Røysamb; Else-Marie Augusti; Annika Melinder
Journal:  Psychopharmacology (Berl)       Date:  2016-02-29       Impact factor: 4.530

7.  The Roles of Maternal Depression, Serotonin Reuptake Inhibitor Treatment, and Concomitant Benzodiazepine Use on Infant Neurobehavioral Functioning Over the First Postnatal Month.

Authors:  Amy L Salisbury; Kevin E O'Grady; Cynthia L Battle; Katherine L Wisner; George M Anderson; Laura R Stroud; Cynthia L Miller-Loncar; Marion E Young; Barry M Lester
Journal:  Am J Psychiatry       Date:  2015-10-30       Impact factor: 18.112

8.  In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder.

Authors:  Nicole B Gidaya; Brian K Lee; Igor Burstyn; Michael Yudell; Erik L Mortensen; Craig J Newschaffer
Journal:  J Autism Dev Disord       Date:  2014-10

Review 9.  Use of Antidepressants During Pregnancy?: What to Consider when Weighing Treatment with Antidepressants Against Untreated Depression.

Authors:  Maria Muzik; Susan E Hamilton
Journal:  Matern Child Health J       Date:  2016-11

Review 10.  Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence.

Authors:  Sura Alwan; Jan M Friedman; Christina Chambers
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.